Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the γδ phenotype from Japan.
Bottom Line: In addition, T-cell receptor (TCR) γδ cells are typically immunostained in frozen sections or determined by TCRβ negativity.Immunophenotypically, some significant differences were found in CD8 and CD56 positivity between our patient series of CTCL-γδ patients with SPTCL features and SPTCL-γδ patients described in the previous literature.Studies on more cases, including those from other countries, are warranted to delineate the clinicopathological features and the significance in these rare lymphomas.
Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The clinical features of our SPTCL patient series are summarized in Table S1. No significant differences in clinical severity (e.g. occurrence of bone marrow involvement or hemophagocytic syndrome) were observed between the SPTCL and CTCL-γδ with SPTCL groups (Table S2). In addition, the log rank test revealed no significant differences in the overall survival distributions by TCR phenotypes (P = 0.6). Moreover, there was no significant difference in relapse-free survival between SPTCL and CTCL-γδ with SPTCL (P = 0.666). On the other hand, the CTCL-γδ without SPTCL patients revealed aggressive clinical behavior. As for clinical features, there was statistical significance in abnormal CT scan result (P = 0.03), initial therapeutic effect (P = 0.01) and status of latest follow up (P = 0.0175) (Table S2). The 5-year overall survival rates of the patients with SPTCL, CTCL-γδ with SPTCL features and CTCL-γδ without SPTCL features were 85.7%, 80.0% and 42.4%, respectively. A statistically significant difference was observed in overall survival among the SPTCL, CTCL-γδ with SPTCL features and CTCL-γδ without SPTCL features groups (P = 0.005; Fig. 4).
Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.